Alpha Emitters Market Size by Type of Radionuclide, Application, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2032
Overview
Global Alpha Emitters Market was valued at USD 937.12 Mn in 2025 and is expected to reach USD 1991.47 Mn by 2032, growing at a CAGR of 11.37% during the forecast period.
Targeted Alpha Therapy (TAT) employing alpha particle emitters is such a new approach to cancer treatment. International Atomic Energy Agency (IAEA) is making a large investment in the design and development of target-specific radiopharmaceuticals.
The report covers the current estimated and forecasted data for the Global Alpha Emitters Market on a global and regional level. The report provides an in-depth analysis of the Global Alpha Emitters Market for the period 2025 – 2032, wherein 2025 is the base year and the period from 2026 to 2032 is the forecast period.
To know about the Research Methodology :- Request Free Sample Report
Data for 2017- 2024 has been included as historical information. The study provides a detailed perspective on market growth, throughout the above forecast period in terms of revenue estimates (in US$ Mn), across the different geographies, which include North America (NA), Europe (EU), Asia Pacific (APAC), Middle East & Africa (MEA) and Latin America (LATAM).
The Global Alpha Emitters Market is segmented by Radionuclide type, Application and Region. The report provides qualitative and quantitative insights on the alpha emitter’s industry trends and a detailed analysis of the market size and growth rate of all segments in the market.
Alpha Emitters Market Dynamics
Cancer therapy with alpha-particle emitters is surely one of the most demanding multidisciplinary endeavours. Alpha emitters achieve the desired biodistribution and associated dose distribution necessary for successful therapy with acceptable acute and long-term toxicities. An increase in awareness among cancer patients about alpha emitter therapy is the driving factor of the global market. A large scope of clinical development in radiotherapy is generating lucrative opportunity for the global market.
Nontargeted healthy cells are damaged, via radiation-induced death or stress of neighbouring cells. This is the disadvantage of alpha emitters’ therapy and restraining factor of the global market.
Global Alpha Emitters Market Scope: Inquire before buying
| Alpha Emitters Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 937.12 USD Mn |
| Forecast Period 2026-2032 CAGR: | 11.37% | Market Size in 2032: | 1991.47 USD Mn |
| Segments Covered: | By Type of Radionuclide | Radium-223 Astatine-211 Actinium-225 Lead-212 Other Radionuclides |
|
| by Application | Prostate Cancer Bone Metastasis Ovarian Cancer Pancreatic Cancer Endocrine Tumors Other Applications |
||
| By End User | Hospitals Diagnostic Centers Other End Users |
||
Alpha Emitters Market, by Segment
In 2025, Radium‑223 held the largest share of the alpha emitter market, commanding 39.20% of revenue. Its dominance is driven by its early regulatory approval in 2013 for metastatic prostate cancer bone lesions, making it a well-established therapy with extensive clinical data supporting its safety and efficacy. The combination of Medicare reimbursement, widespread market familiarity, and a stable supply chain has reinforced its leadership, allowing healthcare providers to adopt it confidently. While emerging radionuclides like Actinium‑225 are experiencing the fastest growth, with a expected 14.05% CAGR through 2032 due to its four-alpha-particle decay chain and broader solid tumor applications, Radium‑223’s historical presence, robust safety profile, and accessibility keep it as the highest-revenue segment in the current market. Niche isotopes like Astatine‑211, with short half-life and outpatient utility, are expanding cautiously, but production limitations and complex chelation chemistry currently restrict their market share.
Alpha Emitters Market, by Region
North America dominated the global alpha emitter market in 2025, accounting for 44.30% of total revenue. The region’s leadership is primarily driven by well-established reimbursement frameworks, strong regulatory clarity, and domestic isotope production capabilities.
The presence of the Oak Ridge National Laboratory plays a critical role in supply stability, with an annual production capacity of approximately 1 Ci of Actinium-225, supporting clinical and commercial development pipelines. Additionally, the regulatory guidance issued by the U.S. Food and Drug Administration for radiopharmaceuticals has streamlined approval pathways, reducing uncertainty for developers.
Strategic capital investments further reinforce regional strength. Major pharmaceutical players such as Novartis and Eli Lilly and Company are expanding U.S.-based manufacturing facilities, enhancing clinical-to-commercial scalability. Collectively, these factors solidify North America’s structural advantage in targeted alpha therapy commercialization.
• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)
The objective of the report is to present a comprehensive analysis of the global alpha emitters market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.
The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the global alpha emitters market dynamics, structure by analyzing the market segments and project the global alpha emitters market clear representation of competitive analysis of key players by price, financial position, by detection and equipment portfolio, growth strategies, and regional presence in the global alpha emitters market make the report investor’s guide.
Recent Developments – Alpha Emitter Market
January 2023 – Orano Med dosed the first patient with 212Pb-GRPR in a Phase I trial, advancing lead-212 alpha radioligand therapy for GRPR-expressing solid tumors and broadening targeted alpha applications beyond prostate and bone cancers.
June 2022 – Alpha Tau Medical Ltd. secured IDE approval from the U.S. Food and Drug Administration to begin a pivotal multicenter study of Alpha DaRT for recurrent cutaneous squamous cell carcinoma.
Alpha Emitters Market, Key Players are:
- Bayer AG
- Novartis AG
- Actinium Pharmaceuticals, Inc.
- Fusion Pharmaceuticals
- Alpha Tau Medical Ltd.
- Telix Pharmaceuticals Ltd.
- RadioMedix Inc.
- Orano Med
- IBA Radiopharma Solutions
- IBA Group
- Lantheus Holdings, Inc.
- ITM Isotope Technologies Munich SE
- Clarity Pharmaceuticals
- Sirius Medical
- NorthStar Medical Radioisotopes, LLC
- Eckert & Ziegler Strahlen‑ und Medizintechnik AG
- Curium Pharma
- Cardinal Health, Inc.
- POINT Biopharma Global Inc.
- NorthStar Medical Technologies
- Siemens Healthineers
- General Electric Company
- Novartis AG
- Isotopia Molecular Imaging Ltd
- Global Medical Solutions